BioSpace News Archive

Elevation Oncology, Inc. today announced the appointment of Darcy Mootz, Ph.D., to its Board of Directors.

YPrime today announced a bold brand evolution initiative that articulates its commitment to provide cutting-edge solutions focused on delivering streamlined and accelerated clinical trials, increasing certainty from study design to data lock.

Biora Therapeutics, Inc today announced participation in a virtual fireside chat hosted by H.C. Wainwright & Co. on Monday, January 29, 2024 at 11:00 AM Eastern / 8:00 AM Pacific.

Coherus BioSciences, Inc. announced it has entered into an agreement to divest its CIMERLI® ophthalmology franchise, inclusive of CIMERLI and its supporting commercial infrastructure, to Sandoz for upfront, all-cash consideration of $170 million plus an additional amount for CIMERLI product inventory and subject to customary working capital adjustments at the closing date.

Sosei Group Corporation will announce its earnings results and present operational highlights for the 12 months ended 31 December 2023 on Tuesday, 13 February 2024.

Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, issued a letter to shareholders.

SIGA Technologies, Inc. today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024, and will also be appointed to the Company’s Board of Directors.

Marker Therapeutics, Inc. announced today that the United States Adopted Names (USAN) Council, and the World Health Organization (WHO) International Nonproprietary Names (INN) expert committee has approved “ neldaleucel ” as the nonproprietary (generic) name for MT-601, a multi-tumor associated antigen (multiTAA)-specific T cell product candidate for the treatment of patients with lymphoma.

60 Degrees Pharmaceuticals, Inc. announced that, following a Type C meeting held on January 17, 2024 with the US Food and Drug Administration, the Company will move forward with a pivotal clinical study of tafenoquine in hospitalized babesiosis patients in the U.S.

Centessa Pharmaceuticals plc today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim’s 6th Annual Biotechnology Conference Date: February 7, 2024 Location: NY, NY Fireside Chat: 9:00 AM ET.